Sacubitril/valsartan in heart failure: efficacy and safety in and outside clinical trials

Heart failure (HF) treatment has changed substantially over the last 30 years, leading to significant reductions in mortality and hospital admissions in patients with HF with reduced ejection fraction (HFrEF). Currently, the optimization of guideline‐directed chronic HF therapy remains the mainstay...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdin, Amr, Schulz, Martin, Riemer, Uwe, Hadëri, Bledar, Wachter, Rolf, Laufs, Ulrich, Bauersachs, Johann, Kindermann, Ingrid, Vukadinović, Davor, Böhm, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9773772/
https://www.ncbi.nlm.nih.gov/pubmed/35921043
http://dx.doi.org/10.1002/ehf2.14097

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9773772/
https://www.ncbi.nlm.nih.gov/pubmed/35921043
http://dx.doi.org/10.1002/ehf2.14097

Ejemplares similares